Navigation Links
Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses in Phase 3 CLL Trial

BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced the publication of preliminary clinical results that show the Company's lead anti-cancer drug, Genasense(R) (oblimersen sodium) injection, can be safely administered by intermittent subcutaneous (SC) injection, as well as by brief intravenous (IV) infusion. These regimens may eventually reduce or eliminate the current requirements for administering Genasense by continuous IV (CIV) infusion. The new schedules also expand the potential for use in combination with anticancer drugs that are administered on a daily or weekly basis. The data were published in proceedings of the annual meeting of the American Society of Clinical Oncology (ASCO) that was held this week in Chicago, IL.

The SC study used a new formulation of Genasense that was concentrated 5- fold greater than that used in previous Phase 3 trials. In a dose-ranging pharmacokinetic (PK) and pharmacodynamic trial, bolus SC injections of 75, 150 and 225 mg yielded dose-proportional plasma concentrations that were associated with down-regulation of Bcl-2 in blood cells. The 225 mg dose level achieved exposure PK parameters that were similar to levels achieved at the 3 mg/kg CIV daily dose level that was tested in the recent Phase 3 trial of Genasense in chronic lymphocytic leukemia (CLL).

A second phase of the program is testing escalating doses of Genasense administered as a 2-hour IV infusion. Single 150 mg doses, as well as repeated 150 mg doses administered daily for 5 consecutive days, have been well-tolerated. To date, the principal adverse events have been reversible skin reactions at the injection site on the SC schedule and transient fever on the brief IV schedule.

"These highly encouraging data represent important next steps that may greatly improve dosing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/4/2015)... , Aug. 4, 2015  Delcath Systems, Inc. (NASDAQ: ... company focused on oncology with an emphasis on the ... two abstracts summarizing data from studies in ... the Delcath Hepatic CHEMOSAT ® Delivery System (CHEMOSAT) will ... Oncology (EADO) annual congress, which will be held in ...
(Date:8/4/2015)... DIEGO , Aug. 4, 2015 ... three-dimensional biology company focused on delivering scientific and ... that the Company has hired Paul Gallant ... vitro tissue service and product business. Mr. Gallant has ... experience in the drug discovery industry, most recently ...
(Date:8/4/2015)... , Aug. 4, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... and epigenetic drivers of cancer, will be presenting at the ... at 1:55 p.m. ET (10:55 a.m. PT) in ... Ph.D., president and CEO of Mirati, will provide a corporate ... will be accessible on the "Investors" page of Mirati,s corporate ...
Breaking Medicine Technology:Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... Designs, a company specializing in fashionable medical ID bracelets ... available in an additional 1,100 pharmacies by the end of ... products to more than 1,800. The company ... offering stylish key chains, necklaces, flash drives and bracelets available ...
... 2011 A new prostate cancer study ... surgical treatment to "watchful waiting" revealed important findings ... currently debating their treatment options. (Photo:   ... offered clinical options for early prostate cancer treatment ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 3
(Date:8/4/2015)... ... ... assistPoint Partners, LLC is proud to announce a ... Through a secure web portal, assistPoint connects Life Sciences, Patients and Providers together ... and workflow solution. This provides cancer center patient advocates, financial counselors and business ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp in a ... have a flip-up face shield. The sleek contours of the new Nightstick NSP-4614B ... their headlamp when raising or lowering their face shield or visor. The 4614 will ...
(Date:8/4/2015)... ... 2015 , ... Worldwide Power Products acquires new assets, certifying ... in Texas. Effective July 1st of this year, Worldwide Power Products acquired operations ... the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 generators in ...
(Date:8/4/2015)... VEGAS, Nevada (PRWEB) , ... August 04, 2015 , ... ... of radio interviews to discuss his new book, The Pain Antidote , which ... Medical Director of Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book ...
Breaking Medicine News(10 mins):Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... have discovered more details about how an energy sensing ... their energy reserves. In a report in the ... showed that a chemical modification on the thermostat protein ... stored energy, and with it, they default to stockpiling ...
... Denise Mann HealthDay Reporter , TUESDAY, Feb. 21 ... to take a second look at the weight loss pill ... about heart problems and possible birth defects. While effective ... denied approval in 2010 because of its potential side effects. ...
... BEER-SHEVA, February 21, 2012 A simple blood test is ... (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that ... Prof. Kapelushnik of BGU,s Faculty of Health Sciences and his ... than a teaspoon of blood. The test uses infrared light ...
... A Cedars-Sinai research scientist has been awarded two national ... Research Project Grant from the National Institutes of Health ... Terrence Town, PhD, is studying drugs that potentially ... plaques that build up in the brain and are ...
... News) -- Watching a lot of movies that feature alcohol ... these teens are more likely to progress to binge drinking, ... findings suggest that U.S. movie makers should adopt the same ... The study included more than 6,500 U.S. kids, aged 10 ...
... British Columbia - Blocking autophagy -- the process of "self-eating" ... way to enhance the effectiveness of a wide variety of ... acidic inner cell part, which acts like a stomach and ... says Ravi K. Amaravadi, MD, an assistant professor of Medicine ...
Cached Medicine News:Health News:Cell energy sensor mechanism discovered 2Health News:FDA Weighs Fate of Qnexa for Weight Loss, Again 2Health News:FDA Weighs Fate of Qnexa for Weight Loss, Again 3Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:Booze in Movies May Fuel Teenage Drinking 2Health News:New combo of chemo and well-known malaria drug delivers double punch to tumors 2
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... explanation of foldable intraocular lenses. The instrument ... placed under the implant and divides the ... helps support both halves of the lens ... in the anterior chamber is avoided. The ...
Medicine Products: